Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

The cause of type 1 diabetes remains unknown and is a ... Identifying the presence of the peptide is a significant step, said Altindis, who collaborated on the project with C. Ronald Kahn, MD, of the ...

There were two primary endpoints in Part B, safety and change in peak C-peptide during a mixed-meal ... is in the Phase 3 portion of the Phase 1/2/3 study in patients with T1D with severe ...

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing ...

Also known as type 1.5 diabetes, here’s what to know about the onset, symptoms, diagnosis, and treatment options for latent ...

But insulin treatment for type 1 diabetes combined with today’s society have caused obesity rates to increase in those patients – and along with that, the use of GLP-1 drugs. GLP-1 drugs mimic the GLP ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company’s type 1 diabetes (T1D) ...